BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
HST Global, Inc. HSTC
14 fiscal years on record · USD · FY2023 reported
SEC FILINGS ONLY
EPS · FY23
—
Dividend / sh · FY23
—
Payout · FY23
—
ROE · FY23
—
Net margin · FY23
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2023 · full 14-year series below
Revenue
Net income
Per share
—
Diluted EPS, FY2023
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2023
ROE
Operating margin—
Net margin—
Return on assets-17040.8%
Returned to shareholders
—
returned in FY2023 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2023
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1,526.00
total assets, end of FY2023
Total assetsUSD 1,526.00
EquityUSD -592,067.00
CashUSD 1,526.00
Current ratio0.00×
Equity funds -38799% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
−0.03
−0.04
0.13
−0.07
0.00
0.00
−0.01
−0.01
−0.01
−0.01
−0.01
−0.03
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.01
0.01
0.01
0.01
0.00
0.00
0.04
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed